الفهرس | Only 14 pages are availabe for public view |
Abstract Neuropeptide Y1 Receptor (NPY1R) is one of the most abundant peptides in the central and peripheral nervous systems of mammals. It has been found to play a role in various physiological functions. Besides, it has been shown to promote proliferation, vascularization and stimulate migration in several cell types and tissues. This is particularly important in malignant tissues, where NPY1R expression may have a prognostic value in the natural history of the disease. The aims of this study were to detect the expression of NPY1R in patients with breast cancer and to assess its correlation with different clinicopathological variables as well as previously known prognostic factors. The study was conducted at Clinical Oncology Department, Menoufia University recruiting patients diagnosed between January 2015 and December 2017. Clinical and pathological data of included patients were extracted from patients’ medical records. Formalin-fixed paraffinembedded blocks of corresponding patients were collected and were subject to further immunohistochemistry for detection of NPY1R expression. Ninety-two cases with median age of 51.5 years were included in the final data analysis, most of whom had a pathological diagnosis of invasive duct carcinoma (95.7%). Neuropeptide Y1 Receptor (NPY1R) tested positive in 50% of malignant cases (n = 46). When we tested NPY1R in different types of tissues, NPY1R was found to be statistically more common in invasive and DCIS cases compared with non-neoplastic cases (50% and 53.3% versus 20.7%; p = 0.002 and p = <0.001, respectively). Statistically significant associations were found between NPY1R expression and presence of metastatic disease, stage, ER expression, molecular subtype, NPI risk group, type of surgery, radiotherapy treatment, hormonal treatment, and type of endocrine therapy. On the other hand, no significant associations could be identified with tumor size, pathology type, patient’s age, lymph node metastases, PR, and her2/neu overexpression. Median OS and median PFS were not reached in both NPY1R positive and NPY1R negative groups, with no statistical difference between the two cohorts. Conclusion: NPY1R is not uncommon, being present in about 50% of malignant breast cancer cases. Its expression has been found to correlate with some features of aggressive disease suggesting a potential prognostic role of the marker in breast cancer. |